Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
Run by ArriVent BioPharma, Inc. · NCT05607550 · Data updated 2026-11-12
Fully enrolled, still running. This study is not taking new participants. Its registered completion date is 2026-10-06.
Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of furmonertinib (firmonertinib) at 2 dose levels (160 mg once daily \[QD\] and 240 mg QD) compared to platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations. A target of approximately 375 patients will be randomized in a 1:1:1 ratio to treatment with furmonertinib 240 mg QD, furmonertinib 160 mg QD, or platinum-based chemotherapy.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 398 (actual) |
| Sponsor | ArriVent BioPharma, Inc. Industry-sponsored |
| Drugs / interventions | furmonertinib 240 mg oral, daily, furmonertinib 160 mg oral, daily, platinum-based chemotherapy |
| Locations | 208 sites (Australia, Brazil, Canada, China, France, Israel, Italy, Japan and more) |
| Trial ID | NCT05607550 on ClinicalTrials.gov |
Who can join: the full rules
Show full inclusion / exclusion criteria
Key Inclusion Criteria: * Histologically or cytologically documented, locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) not amenable to curative surgery or radiotherapy. * Documented results of the presence of an Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutation in tumor tissue or blood from local or central testing. * No prior systemic anticancer therapy regimens received for locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) including prior treatment with any Epidermal Growth Factor Receptor (EGFR)-targeting agents (e.g., previous (EGFR) TKIs, monoclonal antibodies, or bispecific antibodies). * Patients who have received prior neo-adjuvant and/or adjuvant chemotherapy, immunotherapy, or chemo radiotherapy for non-metastatic disease (excluding EGFR-TKIs) must have experienced a treatment free interval of at least 12 months. * Patients with a history of treated CNS metastases or new asymptomatic CNS metastases are eligible.
Where it's running
-
Arrivent Investigative Site
Daphne, Alabama, United States -
Arrivent Investigative Site
Yuma, Arizona, United States -
Arrivent Investigative Site
Fayetteville, Arkansas, United States -
Arrivent Investigative Site
Beverly Hills, California, United States -
Arrivent Investigative Site
Fullerton, California, United States -
Arrivent Investigative Site
Long Beach, California, United States
Show 44 more locations
-
Arrivent Investigative Site
Los Alamitos, California, United States -
Arrivent Investigative Site
Napa, California, United States -
Arrivent Investigative Site
Orange, California, United States -
Arrivent Investigative Site
Orange, California, United States -
Arrivent Investigative site
Sacramento, California, United States -
Arrivent Investigative Site
San Diego, California, United States -
Arrivent Investigative Site
Santa Barbara, California, United States -
Arrivent Investigative Site
Santa Monica, California, United States -
Arrivent Investigative Site
Santa Rosa, California, United States -
Arrivent Investigative Site
Whittier, California, United States -
Arrivent Investigative Site
Hartford, Connecticut, United States -
Arrivent Investigative Site
Norwich, Connecticut, United States -
Arrivent Investigative Site
Fort Myers, Florida, United States -
Arrivent Investigative Site
St. Petersburg, Florida, United States -
Arrivent Investigative Site
The Villages, Florida, United States -
Arrivent Investigative Site
Peoria, Illinois, United States -
Arrivent Investigative Site
Rolling Meadows, Illinois, United States -
Arrivent Investigative Site
Fort Wayne, Indiana, United States -
Arrivent Investigative Site
Indianapolis, Indiana, United States -
Arrivent Investigative Site
South Bend, Indiana, United States -
Arrivent Investigative Site
Bethesda, Maryland, United States -
Arrivent Investigative Site
Frederick, Maryland, United States -
Arrivent Investigative Site
Rockville, Maryland, United States -
Arrivent Investigative Site
Fairhaven, Massachusetts, United States -
Arrivent Investigative Site
Lansing, Michigan, United States -
Arrivent Investigative Site
Bolivar, Missouri, United States -
Arrivent Investigative Site
Kansas City, Missouri, United States -
Arrivent Investigative Site
Saint Joseph, Missouri, United States -
Arrivent Investigative Site
St Louis, Missouri, United States -
Arrivent Investigative Site
Omaha, Nebraska, United States -
Arrivent Investigative Site
Belleville, New Jersey, United States -
Arrivent Investigative Site
Englewood, New Jersey, United States -
Arrivent Investigative Site
Florham Park, New Jersey, United States -
Arrivent Investigative Site
The Bronx, New York, United States -
Arrivent Investigative Site
Goldsboro, North Carolina, United States -
ArriVent Investigative Site
Pinehurst, North Carolina, United States -
Arrivent Investigative Site
Canton, Ohio, United States -
Arrivent Investigative Site
Cincinnati, Ohio, United States -
ArriVent Investigative Site
Cincinnati, Ohio, United States -
Arrivent Investigative Site
Cleveland, Ohio, United States -
Arrivent Investigative Site
Columbus, Ohio, United States -
Arrivent Investigative Site
Oklahoma City, Oklahoma, United States -
Arrivent Investigative Site
Tulsa, Oklahoma, United States -
Arrivent Investigative Site
Salem, Oregon, United States
+158 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Principal investigator: Jamuna Thimmarayappa — ArriVent BioPharm
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.